Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer

Pedro C Barata; Jonathan Assayag; Benjamin Li; Gordon Siu; Alexander Niyazov

doi:10.1001/jamaoncol.2024.0851

Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer

JAMA Oncol. 2024 May 2:e240851. doi: 10.1001/jamaoncol.2024.0851. Online ahead of print.

Authors

Pedro C Barata¹, Jonathan Assayag², Benjamin Li³, Gordon Siu³, Alexander Niyazov³

Affiliations

¹ University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
² Pfizer Inc, Kirkland, Quebec, Canada.
³ Pfizer Inc, New York, New York.

No abstract available

Plain language summary

This cross-sectional study assesses homologous recombination repair mutation genetic testing and associated characteristics among men with metastatic castration-resistant prostate cancer (mCRPC).